For those who are immunocompromised or non-responders, the dose (e.g. 60ug) and number of shots of the vaccine should be increased; for those who do not respond to the three-dose immunization program, three more doses can be administered and the surface antibody in the serum can be monitored 1-2 months after the second vaccination, and if there is still no response, a 60ug recombinant yeast hepatitis B vaccine can be administered. The protection period of antibodies after hepatitis B vaccination generally lasts for 12 years. Surface antibody monitoring and booster injections are not required for the general population, but monitoring can be performed for high-risk groups, and booster injections can be given if antibodies are less than 10ug/ml. Hepatitis B vaccination is also not easy to produce hepatitis B antibodies in patients who have recently suffered from immunocompromising diseases (e.g. chickenpox, typhoid, etc.) or are using immunosuppressive drugs. In this case, the primary disease should be treated first, and personal hygiene should be paid attention to during the period, especially when there is skin and mucous membrane damage, and hepatitis B vaccination should be standardized after the primary disease is cured.